Factor P Antibody (Monoclonal - #2)

A murine monoclonal antibody to an epitope on Factor P.


Product Specifications

Citations 9
Clonality

Monoclonal

Immunogen Purified human protein.
Applications See citations and technical data sheet for application info.
Concentration 1.0-1.2 mg/mL
Conjugate Unconjugated
Cross Reactivity

Human

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A235
Catalog Number (CE) N/A
Size 100 µl
Price (USD) $365.00
Price (EURO) 330,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A murine monoclonal antibody to an epitope on Factor P.

Size 100 µl
Concentration

1.0-1.2 mg/mL

Applications See citations and technical data sheet for application info.
Form Liquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide.
Clonality Monoclonal
Immunogen Purified human protein.
Conjugate Unconjugated
Cross Reactivity Human
Isotype IgG1k
Purity ≥ 95% by SDS PAGE
Source

Mouse

Specificity This monoclonal antibody was raised against purified human Factor P. It does not inhibit function of Factor P.
Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

The function of Properdin (Factor P) is to stabilize the alternative pathway convertase. Its binding to C3bBb extends the half-life of the complex. The concentration in plasma is approximately 20 μg/mL. Factor P has a molecular weight of 224 kDa, consisting of four identical chains of approximately 53 kDa molecular weight. The alternative complement pathway provides innate protection against microbial agents in the absence of specific antibody. The activation of this complement pathway can be triggered by a variety of substances, including microbial polysaccharides or lipids, gram-negative bacterial lipopolysaccharides, and surface determinants present on some viruses, parasites, virally infected mammalian cells and cancer cells. In autoimmune diseases, the alternative complement pathway may contribute directly to tissue damage.

Citations

Title Year Applications Sample Species Sample Sample Details

Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood

2019

ELISA

Human

Whole Blood

Heme, various concentrations

Systemic complement levels in patients with age-related macular degeneration carrying rare or low frequency variants in the CFH gene.

2021

ELISA

Human

Plasma

Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE.

2021

ELISA

Human

Plasma

Congenital Thrombocytopenia

The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure.

2021

ELISA

Human

Plasma

Heart Failure

The complement system is activated in synovial fluid from subjects with knee injury and from patients with osteoarthritis

2016

ELISA

Human

Synovial fluid

A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples.

2014

ELISA, Complement Activation Assay

Human

Plasma

Properdin binding to complement activating surfaces depends on initial C3b deposition

2017

ELISA, WB

Human

Serum

Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans.

2011

IF, FC

Human

Serum

Escalated complement activation during hospitalization is associated with higher risk of 60‐day mortality in SARS‐CoV‐2‐infected patients

2024

ELISA

Human

Plasma

COVID-19